CIK 0000939767 · Large accelerated filer
EXELIXIS, INC.
Sign in to watch- Ticker
- EXEL
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Jan 1
- Incorporated
- DE
- Entity type
- operating
- EIN
- 043257395
- Phone
- 6508377000
- Business address
- 1851 HARBOR BAY PARKWAY, ALAMEDA, CA, 94502
- Former names
- EXELIXIS INC
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2024-01-11 | Senner Christopher J. EVP and CFO | Shares withheld for taxes | −21,862 | $22.86 | $500K | 669,869 |
| 2024-01-11 | Hessekiel Jeffrey EVP, General Counsel & Sec | Grant or award | +71,418 | 604,763 | ||
| 2024-01-11 | Hessekiel Jeffrey EVP, General Counsel & Sec | Shares withheld for taxes | −13,061 | $22.86 | $299K | 591,702 |
| 2024-01-11 | Haley Patrick J. EVP, Commercial | Grant or award | +74,462 | 382,149 | ||
| 2024-01-11 | Haley Patrick J. EVP, Commercial | Shares withheld for taxes | −13,613 | $22.86 | $311K | 368,536 |
| 2024-01-11 | Aftab Dana CSO/EVP Disc & Trans Research | Grant or award | +63,224 | 501,267 | ||
| 2024-01-11 | Aftab Dana CSO/EVP Disc & Trans Research | Shares withheld for taxes | −11,606 | $22.86 | $265K | 489,661 |
| 2024-01-05 | Eckhardt Sue Gail Director | Grant or award | +15,424 | 15,424 | ||
| 2024-01-05 | Eckhardt Sue Gail Director | Grant or award · Option (right to buy) | +30,848 | 30,848 | ||
| 2024-01-05 | Beckerle Mary C Director | Grant or award | +15,424 | 15,424 | ||
| 2024-01-05 | Beckerle Mary C Director | Grant or award · Option (right to buy) | +30,848 | 30,848 | ||
| 2023-12-14 | Haley Patrick J. EVP, Commercial | Option exercise 10b5-1 | +50,000 | $16.29 | $815K | 357,687 |
| 2023-12-14 | Haley Patrick J. EVP, Commercial | Sale 10b5-1 | −50,000 | $23.35 | $1.2M | 307,687 |
| 2023-12-14 | Haley Patrick J. EVP, Commercial | Option exercise · Option (right to buy) 10b5-1 | −50,000 | 0 | ||
| 2023-12-13 | Hessekiel Jeffrey EVP, General Counsel & Sec | Sale 10b5-1 | −25,000 | $23.01 | $575K | 533,345 |
| 2023-12-12 | Haley Patrick J. EVP, Commercial | Sale 10b5-1 | −14,149 | $22.50 | $318K | 307,687 |
| 2023-12-04 | Hessekiel Jeffrey EVP, General Counsel & Sec | Sale 10b5-1 | −25,000 | $22.06 | $552K | 558,345 |
| 2023-11-30 | Hessekiel Jeffrey EVP, General Counsel & Sec | Sale 10b5-1 | −25,000 | $22.01 | $550K | 583,345 |
| 2023-11-27 | JOHNSON DAVID EDWARD Director | Sale | −120,409 | $21.61 | $2.6M | 790,321 |
| 2023-11-27 | JOHNSON DAVID EDWARD Director | Purchase | +120,409 | $21.61 | $2.6M | 910,730 |
Page 17 of 20 · 381 trades